Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1587-1591

  Kim, Seo Ju ^a   Chung, Myoung Ja ^a   Kim, Jong Suk ^a   Kim, Bumseok ^b   Park, Woo Hyun ^a   Kim, Suhn Hee ^a   Kim, Sung Zoo ^a   Lee, Ju Seog ^c   Kim, Soo Mi ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Chonbuk National University   (South Korea)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Esophageal adenocarcinoma cells; G 2 M arrest; Paclitaxel

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSAY; CANCER CELL; CANCER STRAIN SKGT4; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; ENZYME ACTIVATION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; ESOPHAGEAL NEOPLASMS; HUMANS; PACLITAXEL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054824456     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1135     Document Type: Article

References (34)

1. Brown LM, Devesa SS and Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100: 1184-1187, 2008.
2. Jemal A, Center MM, De Santis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
3. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
4. Bollschweiler E, Wolfgarten E, Gutschow C and Holscher AH: Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92: 549-555, 2001. (Pubitemid 32735190)
5. Mariette C, Balon JM, Piessen G, Fabre S, van Seuningen I and Triboulet JP: Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 97: 1616-1623, 2003. (Pubitemid 36350704)
6. Kim SM, Park YY, Park ES, et al.: Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 5: e15074, 2010.
7. Bosset JF, Gignoux M, Triboulet JP, et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: 161-167, 1997. (Pubitemid 27306287)
8. Tepper J, Krasna MJ, Niedzwiecki D, et al.: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092, 2008.
9. Legha SS, Ring S, Papadopoulos N, Raber M and Benjamin RS: A phase II trial of taxol in metastatic melanoma. Cancer 65: 2478-2481, 1990. (Pubitemid 20168933)
10. Holmes FA, Walters RS, Theriault RL, et al.: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
11. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD and Goldberg GL: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748-1753, 1992. (Pubitemid 23059952)
12. Stearns ME and Wang M: Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 52: 3776-3781, 1992.
13. Speicher LA, Barone L and Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52: 4433-4440, 1992.
14. Tishler RB, Geard CR, Hall EJ and Schiff PB: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497, 1992.
15. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM and Kelsen DP: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086-1091, 1994. (Pubitemid 24228477)
16. Faried A, Faried LS, Kimura H, et al.: Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines. Cancer Chemother Pharmacol 57: 301-308, 2006.
17. Toiyama Y, Tanaka K, Konishi N, et al.: Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45. Cancer Chemother Pharmacol 57: 368-375, 2006.
18. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
19. Peter M and Herskowitz I: Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79: 181-184, 1994. (Pubitemid 24324907)
20. Elledge SJ and Harper JW: Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847-852, 1994. (Pubitemid 24357916)
21. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994. (Pubitemid 24268576)
22. Kothakota S, Azuma T, Reinhard C, et al.: Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 278: 294-298, 1997. (Pubitemid 27450877)
23. Nunez G, Benedict MA, Hu Y and Inohara N: Caspases: the proteases of the apoptotic pathway. Oncogene 17: 3237-3245, 1998. (Pubitemid 29043976)
24. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68: 1104-1109, 1993. (Pubitemid 23356660)
25. Chang YF, Li LL, Wu CW, et al.: Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77: 14-18, 1996. (Pubitemid 26002731)
26. Molinari M: Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 33: 261-274, 2000.
27. Doree M and Galas S: The cyclin-dependent protein kinases and the control of cell division. FASEB J 8: 1114-1121, 1994. (Pubitemid 24361516)
28. Lewin B: Driving the cell cycle: M phase kinase, its partners, and substrates. Cell 61: 743-752, 1990.
29. Sleiman RJ, Catchpoole DR and Stewart BW: Drug-induced death of leukaemic cells after G2/M arrest: higher order DNA fragmentation as an indicator of mechanism. Br J Cancer 77: 40-50, 1998. (Pubitemid 28029771)
30. Wei Y, Mizzen CA, Cook RG, Gorovsky MA and Allis CD: Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. Proc Natl Acad Sci USA 95: 7480-7484, 1998. (Pubitemid 28293278)
31. Wei Y, Yu L, Bowen J, Gorovsky MA and Allis CD: Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 97: 99-109, 1999. (Pubitemid 29165893)
32. Susin SA, Zamzami N and Kroemer G: Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1366: 151-165, 1998. (Pubitemid 28467029)
33. Kroemer G and Reed JC: Mitochondrial control of cell death. Nat Med 6: 513-519, 2000. (Pubitemid 30305900)
34. Barth H, Hoffmann I and Kinzel V: Radiation with 1 Gy prevents the activation of the mitotic inducers mitosis-promoting factor (MPF) and cdc25-C in HeLa cells. Cancer Res 56: 2268-2272, 1996. (Pubitemid 26154071)